Novo Nordisk's reign as Europe's most valuable company is facing a challenge from US rival Eli Lilly. Lilly's weight-loss drug, Zepbound, is gaining market share, while Novo's experimental drug showed less impressive results. This competition mirrors the Nokia-Apple rivalry, raising concerns about Europe's ability to maintain its competitive edge.
